Foamix Pharmaceuticals Ltd (FOMX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Foamix Pharmaceuticals Ltd (FOMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7945
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Foamix Pharmaceuticals Ltd (Foamix), formerly Foamix Ltd is a pharmaceutical company that develops and commercializes proprietary topical drugs for various dermatological therapies. The company’s product candidates include FMX101, a minocycline foam which is intended for the treatment of moderate-to-severe acne; FMX 103, for the treatment of rosacea; FMX102, for impetigo; and FDX104, a doxycycline foam for the management of acne-like rash. It also develops various early stage products. The company has partnership with various pharmaceutical companies to develop its product candidates. It has presence in Israel and the US. Foamix is headquartered in Rehovot, Israel.

Foamix Pharmaceuticals Ltd (FOMX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Foamix Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Foamix Pharma Raises USD16.2 Million in Private Placement of Shares 11
Partnerships 12
Foamix Enters into Co-Development Agreement with National Eye Institute 12
Licensing Agreements 13
Merz North America Enters Into Licensing Agreement With Foamix 13
Equity Offering 14
Foamix Pharma Raises USD80.5 Million in Public Offering of Shares 14
Foamix Pharma Plans to Raise Funds in Public Offering of Shares 16
Foamix Pharma Prices Public Offering of Shares for USD57 Million 17
Foamix Pharma Raises USD69 Million in Public Offering of Shares 19
Foamix Pharma Raises USD40 Million in IPO of Shares 21
Foamix Pharmaceuticals Ltd – Key Competitors 23
Foamix Pharmaceuticals Ltd – Key Employees 24
Foamix Pharmaceuticals Ltd – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 08, 2018: Foamix reports second quarter 2018 financial results and provides corporate update 26
May 08, 2018: Foamix Announces First Quarter 2018 Financial Results 28
Feb 28, 2018: Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update 29
Nov 15, 2017: Foamix Reports Third Quarter 2017 Financial Results and Provides Business Update 31
Aug 08, 2017: Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update 34
May 09, 2017: Foamix Reports First Quarter 2017 Financial Results and Provides Business Update 38
Feb 22, 2017: Foamix Reports Year End 2016 Financial Results and Provides Business Update 41
Corporate Communications 42
Jan 03, 2018: Foamix Names Mr. David Domzalski as a Member of the Board of Foamix Pharmaceuticals 42
Jun 29, 2017: Foamix Pharmaceuticals Appoints David Domzalski as Chief Executive Officer 43
Other Significant Developments 44
Apr 16, 2018: Foamix Announces $16 Million Investment By OrbiMed 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Foamix Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Foamix Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Foamix Pharma Raises USD16.2 Million in Private Placement of Shares 11
Foamix Enters into Co-Development Agreement with National Eye Institute 12
Merz North America Enters Into Licensing Agreement With Foamix 13
Foamix Pharma Raises USD80.5 Million in Public Offering of Shares 14
Foamix Pharma Plans to Raise Funds in Public Offering of Shares 16
Foamix Pharma Prices Public Offering of Shares for USD57 Million 17
Foamix Pharma Raises USD69 Million in Public Offering of Shares 19
Foamix Pharma Raises USD40 Million in IPO of Shares 21
Foamix Pharmaceuticals Ltd, Key Competitors 23
Foamix Pharmaceuticals Ltd, Key Employees 24
Foamix Pharmaceuticals Ltd, Subsidiaries 25

List of Figures
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Foamix Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Foamix Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Foamix Pharmaceuticals Ltd (FOMX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ArmaGen Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a clinical stage biotechnology company that develops novel therapies for the treatment of neurological disorders. The company’s pipeline products include AGT-181, AGT-182, AGT-183, AGT-184, AGT-187, AGT-115, AGT-190, AGT-110 and AGT …
  • H&E Equipment Services Inc (HEES):企業の財務・戦略的SWOT分析
    Summary H&E Equipment Services Inc (H&E Equipment) is an integrated equipment company that provides rentals and sales services. The company rents, sells and provides parts and service support for new and used earthmoving equipments, material handling, forestry, concrete, industrial and heavy equipme …
  • Universal Health Services Inc (UHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Universal Health Services Inc (UHS) is a healthcare service provider the offers acute care and behavioral health services. The center provides services such as general and specialty surgery, internal medicine, obstetrics, oncology, diagnostic care, coronary care, emergency room care, radiolo …
  • Schlumberger Ltd (SLB):企業の財務・戦略的SWOT分析
    Schlumberger Ltd (SLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ornua Co-operative Limited:企業の戦略・SWOT・財務情報
    Ornua Co-operative Limited - Strategy, SWOT and Corporate Finance Report Summary Ornua Co-operative Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Pharma Two B Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharma Two B Ltd (Pharma Two) is a drug development company that develops and manufactures drugs for the treatment of Parkinson's disease and cancer. The company provides combination products in preclinical state and generic products including P2B 005, P2B 006, P2B 007, P2B 008 and P2B 009, …
  • The Miyazaki Bank Ltd.:企業の戦略・SWOT・財務情報
    The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Miyazaki Bank Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Saft Groupe SA:企業の戦略的SWOT分析
    Saft Groupe SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • PFB Corp (PFB):企業の財務・戦略的SWOT分析
    Summary PFB Corp (PFB) is a diversified company. The company manufactures and distributes insulating building products and technologies. The company provides EPS product solutions such as insulspan structural insulating panel systems, rating system, insulated concrete forming system, timber framing …
  • Wabash Valley Power Association, Inc.:企業の戦略的SWOT分析
    Wabash Valley Power Association, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Cancer Research UK-製薬・医療分野:企業M&A・提携分析
    Summary Cancer Research UK (CRUK) is a research institution which offers clinical research services to treat cancer. The institute offers research services for womb cancer, lung cancer, bladder cancer, bone cancer, bowel cancer, brain tumours, breast cancer, carcinoid, cervical cancer, children's ca …
  • Cyxone AB-製薬・医療分野:企業M&A・提携分析
    Summary Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company’s lead product include T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis …
  • Synthetic Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Synthetic Genomics Inc (Synthetic Genomics) is a provider of synthetic biology and synthetic genomics solutions. The company offers DNA synthesis services, instrumentation, reagents, and bioinformatics services and software packages. It offers solutions in genomics research, bioproduction, a …
  • Battelle Memorial Institute:医療機器:M&Aディール及び事業提携情報
    Summary Battelle Memorial Institute (Battelle) is a nonprofit research and development (R&D) organization. It carries out discovery, design, development, and manufacture of products, and renders its services to government and commercial customers. The institute manages national laboratories and main …
  • Bank of Montreal:企業の戦略・SWOT・財務分析
    Bank of Montreal - Strategy, SWOT and Corporate Finance Report Summary Bank of Montreal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). …
  • EMCOR Group, Inc.:企業の戦略・SWOT・財務情報
    EMCOR Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary EMCOR Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • McDermott International, Inc.:企業の戦略・SWOT・財務情報
    McDermott International, Inc. - Strategy, SWOT and Corporate Finance Report Summary McDermott International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Lepanto Consolidated Mining Company:企業の戦略・SWOT・財務情報
    Lepanto Consolidated Mining Company - Strategy, SWOT and Corporate Finance Report Summary Lepanto Consolidated Mining Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Trilogy Health Services LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Trilogy Health Services LLC (Trilogy) is a healthcare service provider that offers senior living and long-term healthcare services. The center offers services such as independent living, assisted living, skilled nursing, memory care, rehabilitation, adult day service, respite care, home heal …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆